Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma

Jordan Gauthier • 2 Dec 2018
ASH 2018
Acute Lymphoblastic Leukemia B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T JCAR021

Jordan Gauthier, MD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, covers the data for JCAR021, bearing a human CD19-binding single chain variable fragment, for relapsed/refractory acute lymphoblastic leukemia (ALL) and B-cell lymphoma (NCT03103971). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Jordan Gauthier

3:40
Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier • 28 Jan 2021
3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
3:50
CLL outcomes after CD19 CAR-T with ibrutinib
Jordan Gauthier • 30 Mar 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals